Boston Scientific (NYSE:BSX) Reaches New 12-Month Low – Should You Sell?

Boston Scientific Corporation (NYSE:BSX)’s share price reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $46.91 and last traded at $47.1930, with a volume of 6205770 shares traded. The stock had previously closed at $48.34.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: BTIG reiterated a bullish view on Boston Scientific, highlighting the stock’s low forward P/E and implying substantial upside from current levels. The note reinforces the idea that the recent selloff may have gone too far relative to fundamentals. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Neutral Sentiment: Boston Scientific remains well covered by analysts, with several recent firms keeping buy or outperform ratings and price targets still clustered well above the current share price range, suggesting Wall Street still sees recovery potential. Boston Scientific Stock (BSX) Opinions on Recent Stock Decline
• Neutral Sentiment: Recent market commentary noted that Boston Scientific has traded sharply lower after a guidance reduction, with investors debating whether the decline is a buying opportunity or a sign of slower growth in key businesses such as WATCHMAN and ablation. Boston Scientific Stock (BSX) Opinions on Recent Stock Decline
• Negative Sentiment: Erste Group trimmed FY2026 and FY2027 EPS estimates for Boston Scientific, adding to the cautious tone around earnings expectations and weighing on sentiment. MarketBeat BSX research update
• Negative Sentiment: Short interest in Boston Scientific rose sharply in May, indicating that more traders are positioning for further downside and adding a bearish signal to the stock’s recent move lower.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on BSX shares. Oppenheimer set a $90.00 price objective on shares of Boston Scientific in a research report on Thursday, April 23rd. UBS Group decreased their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $77.00 price objective on shares of Boston Scientific in a research report on Monday, May 18th. Raymond James Financial reaffirmed an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Finally, Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.92.

Boston Scientific Stock Down 1.1%

The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The business’s fifty day moving average price is $56.99 and its 200 day moving average price is $75.49. The firm has a market capitalization of $71.07 billion, a PE ratio of 19.99, a PEG ratio of 0.92 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders acquired 9,800 shares of company stock valued at $554,012. Company insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rathbones Group PLC increased its stake in Boston Scientific by 15.2% during the 1st quarter. Rathbones Group PLC now owns 3,179,435 shares of the medical equipment provider’s stock worth $199,510,000 after buying an additional 419,778 shares during the period. First National Bank of Mount Dora Trust Investment Services purchased a new stake in Boston Scientific during the 1st quarter worth $8,455,000. DV Trading LLC increased its stake in Boston Scientific by 348,200.0% during the 1st quarter. DV Trading LLC now owns 3,483 shares of the medical equipment provider’s stock worth $219,000 after buying an additional 3,482 shares during the period. Optiver Holding B.V. purchased a new stake in Boston Scientific during the 1st quarter worth $852,000. Finally, Caerus Investment Advisors LLC purchased a new stake in Boston Scientific during the 1st quarter worth $236,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.